Previous 10 | Next 10 |
home / stock / nvo / nvo articles
Maker of ‘miracle’ weight loss drugs Ozempic and Wegovy, Novo Nordisk A/S (NYSE:NVO) has announced the acquisition of three fill-finish...
Eli Lilly (NYSE:LLY) reports its fourth quarter earnings next week and, as Novo Nordisk (NYSE:NVO) did on Wednesday, is expected to wow investors w...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported fourth quarter of 2023 sales of DKK 65.86 billion ($9.5 billion compared to the consensus of...
Eli Lilly And Co (NYSE:LLY) is reportedly engaged in discussions with the German government to lift the ban on the public health system coveri...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved, Thursday, a four-dose version of the diabetes and weight manageme...
Three individuals sought medical attention for dangerously low blood sugar in the U.S. in the previous year, having taken suspected fake versions o...
Jim Cramer, the host of CNBC’s “Mad Money,” has hinted at the possibility of Tesla Inc (NASDAQ:TSLA) being replaced by Eli Lilly ...
The European Medicines Agency (EMA) is set to discuss extending the application of Novo Nordisk A/S’s (NYSE:NVO) weight loss drug, ...
In a recent interview, Kasim Kutay, Chief Executive Officer of Novo Holdings, announced the company’s ambitious plans for further a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...